Applications of these two approaches include treating the effects of neurological diseases such as Down syndrome, Alzheimer's and Parkinson's; healing damaged heart tissue after heart attacks; increasing bone and muscle strength in the severely frail; and protecting organs after infection or transplantation. Fate will also tackle devastating cancers, such as pancreatic and colorectal cancer, by developing drugs to prevent the expansion and maturation of cancer stem cells.
Fate's approach differs significantly from others working with stem cells
To date, most stem cell companies have focused on cell therapy using harvested cells from cord blood or other tissues. In contrast, Fate's approach focuses exclusively on traditional therapeutics, namely small molecules and protein therapeutics, to direct cell fate. In addition to its novel approach, Fate's work has potential broad application across all degenerative diseases, developmental disorders and cancers, and in enabling the creation of healthy patient-identical cells for transplantation.
"We have looked at investing in many stem cell companies, but the science and commercial reality just wasn't there yet," said Robert Nelsen, founding partner of ARCH Venture Partners, whose firm co-founded Fate. "Now is the perfect storm; the right biology breakthroughs; a targeted way to use real drugs; and the leading scientists, entrepreneurs, and investors -- all in the same company to develop breakthrough medicines."
Founders' breakthroughs are breathtaking in scope and implication
Fate's founders include researchers from across the United States and
multiple scientific disciplines, including basic biology, biological
chemistry and translational medicine. As authors of many of the most
far-ranging breakthroughs in stem cell science, the team is defining the
changes in the field:
-- Philip Beachy, Ph.D., Stanford University Institute for Stem Cell
|SOURCE Fate Therapeutics|
Copyright©2007 PR Newswire.
All rights reserved